Novo Nordisk filed a flurry of lawsuits across the United States last week claiming various entities, including weight loss clinics and medical spas, violated its trademark and falsely advertised its semaglutide products, Ozempic, Wegovy and Rybelsus.
The pharmaceutical company filed nine lawsuits accusing the defendants of misappropriating its marks to sell semaglutide-based compounded drugs for weight loss without approval from the U.S. Food and Drug Administration. Nearly half of the cases were filed in Florida with the company also filing suit in Tennessee, Montana, Colorado, Illinois and Texas.
